Grunwell Jocelyn R, Travers Curtis, McCracken Courtney E, Scherrer Patricia D, Stormorken Anne G, Chumpitazi Corrie E, Roback Mark G, Stockwell Jana A, Kamat Pradip P
1Department of Pediatrics, Emory University School of Medicine, Children's Healthcare of Atlanta at Egleston, Atlanta, GA.2Department of Pediatrics, Emory University School of Medicine, Atlanta, GA.3Department of Pediatrics, Baylor College of Medicine, Children's Hospital of San Antonio, San Antonio, TX.4Department of Pediatrics, Case Western Reserve University, Rainbow Babies' and Children's Hospital, Cleveland, OH.5Department of Pediatrics, Baylor College of Medicine, Texas Children's Hospital, Houston, TX.6Department of Pediatrics, University of Minnesota, Minneapolis, MN.
Pediatr Crit Care Med. 2016 Dec;17(12):1109-1116. doi: 10.1097/PCC.0000000000000920.
Most studies of ketamine administered to children for procedural sedation are limited to emergency department use. The objective of this study was to describe the practice of ketamine procedural sedation outside of the operating room and identify risk factors for adverse events.
Observational cohort review of data prospectively collected from 2007 to 2015 from the multicenter Pediatric Sedation Research Consortium.
Sedation services from academic, community, free-standing children's hospitals and pediatric wards within general hospitals.
Children from birth to 21 years old or younger.
None.
Describe patient characteristics, procedure type, and location of administration of ketamine procedural sedation. Analyze sedation-related adverse events and severe adverse events. Identify risk factors for adverse events using multivariable logistic regression. A total of 22,645 sedations performed using ketamine were analyzed. Median age was 60 months (range, < 1 mo to < 22 yr); 72.0% were American Society of Anesthesiologists-Physical Status less than III. The majority of sedations were performed in dedicated sedation or radiology units (64.6%). Anticholinergics, benzodiazepines, or propofol were coadministered in 19.8%, 57.9%, and 35.4%, respectively. The overall adverse event occurrence rate was 7.26% (95% CI, 6.92-7.60%), and the frequency of severe adverse events was 1.77% (95% CI, 1.60-1.94%). Procedures were not completed in 39 of 19,747 patients (0.2%). Three patients experienced cardiac arrest without death, all associated with laryngospasm.
This is a description of a large prospectively collected dataset of pediatric ketamine administration predominantly outside of the operating room. The overall incidence of severe adverse events was low. Risk factors associated with increased odds of adverse events were as follows: cardiac and gastrointestinal disease, lower respiratory tract infection, and the coadministration of propofol and anticholinergics.
大多数关于氯胺酮用于儿童程序性镇静的研究仅限于急诊科使用。本研究的目的是描述手术室以外氯胺酮程序性镇静的应用情况,并确定不良事件的危险因素。
对2007年至2015年从多中心儿科镇静研究联盟前瞻性收集的数据进行观察性队列回顾。
学术性、社区性、独立儿童医院以及综合医院儿科病房的镇静服务。
出生至21岁及以下的儿童。
无。
描述患者特征、手术类型以及氯胺酮程序性镇静的给药地点。分析与镇静相关的不良事件和严重不良事件。使用多变量逻辑回归确定不良事件的危险因素。共分析了22645例使用氯胺酮进行的镇静。中位年龄为60个月(范围,<1个月至<22岁);72.0%的患者美国麻醉医师协会身体状况分级小于III级。大多数镇静在专门的镇静或放射科进行(64.6%)。分别有19.8%、57.9%和35.4%的患者联合使用了抗胆碱能药物、苯二氮䓬类药物或丙泊酚。总体不良事件发生率为7.26%(95%CI,6.92 - 7.60%),严重不良事件发生率为1.77%(95%CI,1.60 - 1.94%)。19747例患者中有39例(0.2%)手术未完成。3例患者发生心脏骤停但未死亡,均与喉痉挛有关。
这是对一个主要在手术室以外前瞻性收集的大型儿科氯胺酮给药数据集的描述。严重不良事件的总体发生率较低。与不良事件发生几率增加相关的危险因素如下:心脏和胃肠道疾病、下呼吸道感染以及丙泊酚和抗胆碱能药物的联合使用。